ReviewFrontiers in immunology2016
Manufacturing Natural Killer Cells as Medicinal Products.
Review in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of natural killer cell therapy for the treatment of advanced non-small cell lung cancer: A meta-analysis and systematic review.Immunologic research · 2025Pooled it
- Identifying SARS-CoV-2 'memory' NK cells from COVID-19 convalescent donors for adoptive cell therapy.Immunology · 2022Trial
- Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapy.Pharmaceutical science advances · 2026Review
- Donor NKG2A/NKG2C Immunophenotype Influences the GMP-Compliant Manufacturing Potential of NK Cells for Adoptive Immunotherapy.Cancers · 2026Article
- HOPX is required for the generation of umbilical cord blood-derived memory-like NK cells induced by three cytokines.Frontiers in immunology · 2026Article
- Article
- Bulk RNA sequencing reveals the comprehensive genetic characteristics of human cord blood-derived natural killer cells.Regenerative therapy · 2024Article
- Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model.Science advances · 2022Article
- Advances in NK cell production.Cellular & molecular immunology · 2022Review
- Preclinical and clinical studies of CAR-NK-cell therapies for malignancies.Frontiers in immunology · 2022Review
- Natural killer cell‑based immunotherapy for lung cancer: Challenges and perspectives (Review).Oncology reports · 2021Review
- Review
- Extracellular mRNA transported to the nucleus exerts translation-independent function.Nature communications · 2021Article
- Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.British journal of haematology · 2021Review
- NK cell-based cancer immunotherapy: from basic biology to clinical development.Journal of hematology & oncology · 2021Review
- The Antitumor Effect of Heparin is not Mediated by Direct NK Cell Activation.Journal of clinical medicine · 2020Article
- NK Cell-Based Immunotherapies in Cancer.Immune network · 2020Review
- Article
- Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer.Frontiers in immunology · 2020Review
- Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural Killer (NK) cells are innate lymphoid cells (ILC) with cytotoxic and regulatory properties. Their functions are tightly regulated by an array of inhibitory and activating receptors, and their mechanisms of activation strongly differ from antigen recognition in the context of human leukocyte antigen presentation as needed for T-cell activation. NK cells thus offer unique opportunities for new and improved therapeutic manipulation, either
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.